Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development and validation of a patient‐reported outcome measure to assess symptom burden after chimeric antigen receptor T‐cell therapy
Xin Shelley Wang, Samer A. Srour, Tito R. Mendoza, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 4, pp. 738-746
Closed Access | Times Cited: 10

Showing 10 citing articles:

Mapping immune checkpoint inhibitor side effects to item libraries for use in real-time side effect monitoring systems
Julia Lai‐Kwon, Michael Jefford, Stephanie Best, et al.
Journal of Patient-Reported Outcomes (2025) Vol. 9, Iss. 1
Open Access
Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a Multinational Association for Supportive Care in Cancer modified Delphi survey
Julia Lai‐Kwon, Claudia Rutherford, Stephanie Best, et al.
Supportive Care in Cancer (2025) Vol. 33, Iss. 2
Closed Access
Unmet needs and lived experience of patients receiving CAR T-cell therapy
P.G. O’Shea, P. Connor Johnson, Areej El‐Jawahri, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-11
Closed Access
Calidad de vida y estado emocional de los pacientes candidatos a terapia CAR-T: rol de la enfermera de práctica avanzada
Mercedes Montoro-Lorite, Gloria García, Cristina Moreno-García, et al.
Enfermería Clínica (2025), pp. 502188-502188
Closed Access
Long‐term survivorship care after CAR‐T cell therapy
Robert Puckrin, Kareem Jamani, Víctor H. Jiménez‐Zepeda
European Journal Of Haematology (2023) Vol. 112, Iss. 1, pp. 41-50
Open Access | Times Cited: 9
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies
Foram Khatsuria, Christel McMullan, Olalekan Lee Aiyegbusi, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 10, pp. e476-e488
Closed Access | Times Cited: 2
Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress
Emmanuelle Tchernonog, Aline Moignet, Amélie Anota, et al.
Haematologica (2024)
Open Access | Times Cited: 1
Evolving strategies for addressing CAR T-cell toxicities
Alexander W. Rankin, Brynn B. Duncan, Cecily Allen, et al.
Cancer and Metastasis Reviews (2024) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies
Xin Shelley Wang, Samer A. Srour
Hematology (2024) Vol. 2024, Iss. 1, pp. 102-108
Closed Access
A Predictive Model of Severe Cytokine Release Syndrome After Coadministration of CD19- and CD22-Chimeric Antigen Receptor T-Cell Therapy in Children With B-Cell Hematological Malignancies Based on Patient-Reported Outcomes
Kangjia Zhao, Jiwen Sun, Mengxue He, et al.
Cancer Nursing (2023) Vol. 48, Iss. 1, pp. 3-11
Closed Access
Page 1

Scroll to top